Veru Inc News

Express News | Veru Announces Steven B. Heymsfield M.d. as the Principal Investigator for Its Enobosarm Phase 2B Clinical Trial for High Quality Weight Loss

ReutersMay 15 08:30 ET

Veru Initiated at Buy by B. Riley Securities

Veru Initiated at Buy by B. Riley Securities

Dow JonesMay 14 05:58 ET

Express News | B. Riley Securities Initiates Coverage On Veru With Buy Rating, Announces Price Target of $5

BenzingaMay 14 05:48 ET

Express News | HC Wainwright & Co. Reiterates Buy on Veru, Maintains $3 Price Target

BenzingaMay 13 05:47 ET

Veru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial Recovery

Yahoo FinanceMay 9 03:01 ET

Veru Inc | 10-Q: Quarterly report

Futu NewsMay 8 13:13 ET · Announcements

Veru Inc. (VERU) Fiscal 2024 Q2 Earnings: Clinical Advances Amid Financial Strains

Yahoo FinanceMay 8 08:39 ET

Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M

06:33 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M

MT NewswiresMay 8 06:33 ET

Veru Q2 2024 Adj EPS $(0.07) Misses $(0.05) Estimate, Sales $4.10M Beat $3.00M Estimate

Veru (NASDAQ:VERU) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. The company reported quarterly sales of $4.10 million which bea

BenzingaMay 8 06:33 ET

Express News | Veru Inc: Phase 2B Clinical Study of Enobosarm in Combination With Semaglutide (Wegovy ) for High Quality Weight Loss Is Actively Enrolling

ReutersMay 8 06:31 ET

Veru 2Q Loss/Shr 7c >VERU

Veru 2Q Loss/Shr 7c >VERU

Dow JonesMay 8 06:31 ET

Express News | Veru Q2 Revenue USD 4.1 Million

ReutersMay 8 06:30 ET

Express News | Veru Q2 Gross Profit USD 700 Thousand

ReutersMay 8 06:30 ET

Express News | Veru Q2 Net Income USD -10 Million

ReutersMay 8 06:30 ET

Express News | Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of Its Enobosarm High Quality Weight Loss Clinical Program

ReutersMay 8 06:30 ET

Veru 2Q Rev $4.14M >VERU

Veru 2Q Rev $4.14M >VERU

Dow JonesMay 8 06:30 ET

Critical Insights From Veru Analyst Ratings: What You Need To Know

4 analysts have shared their evaluations of Veru (NASDAQ:VERU) during the recent three months, expressing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table belo

BenzingaMay 6 09:01 ET

Veru Is Maintained at Buy by HC Wainwright & Co.

Veru Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 6 05:43 ET

Express News | HC Wainwright & Co. Maintains Buy on Veru, Raises Price Target to $3

BenzingaMay 6 05:33 ET

Veru Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 87.5% HC Wainwright & Co. $2 → $3 Maintains Buy 04/15/2024 212.5% Oppenheimer $7 → $5 Reiterate

BenzingaMay 6 05:32 ET